Future Cardia Expands Collaboration with Artella Solutions to Advance Cardiac Monitoring Technology

The device is designed to deliver long-term ECG data for rhythm evaluation and is currently under regulatory review. The company said it has not been cleared or approved by the FDA for commercial use.

Future Cardia has expanded its partnership with remote cardiac monitoring company Artella Solutions as it continues developing its implantable cardiac monitoring device.

The device is designed to deliver long-term ECG data for rhythm evaluation and is currently under regulatory review. The company said it has not been cleared or approved by the FDA for commercial use.

The two companies first collaborated during Future Cardia’s pre-FDA phase by integrating Artella’s active state monitoring platform with Future Cardia’s investigational implantable sensor to support secure ECG data transfer for clinical assessment.

Both organisations are now evaluating how Artella’s remote cardiac monitoring platform can be incorporated into Future Cardia’s broader data and workflow ecosystem.

Future Cardia noted that Artella’s device-agnostic patch and telemetry platform offer an opportunity to assess data transfer, interoperability, and workflow optimisation.

“Future Cardia is bringing an implantable solution to a market that urgently needs innovation,” Sepand Moshiri, Artella Solutions cofounder and CEO, said in a statement. “Artella and its holding company CorMedica Group were built to partner with technologies like this in which data, automation, clinical oversight and Elite Customer Service can meaningfully change outcomes for patients and providers.”

Future Cardia CEO Jae Bang said the company was created with the belief that long-term physiologic data can improve cardiac understanding.

“Our collaboration with Artella represents an important step in exploring how implantable and external monitoring technologies can work together to advance data integration and clinical workflow capabilities,” Bang said in a statement.

In the broader cardiac monitoring market, 2024 saw Samsung spinoff Wellysis partner with Artella Solutions to introduce a remote monitoring service in the United States using its FDA-approved S-Patch ECG device and the extended-use S-Patch ExL.

Other players include AccurKardia and HeartBeam, which partnered earlier this year to integrate AccurKardia’s automated ECG interpretation software into HeartBeam’s devices.

Stay tuned for more such updates on Digital Health News